

Common Ground:

Microbial Persistence, Immune Dysregulation and Inflammation Following SARS-CoV-2 and other Infection-Associated Chronic Illnesses

Timothy J. Henrich MD, MMSc
Associate Professor of Medicine
Division of Experimental Medicine
University of California San Francisco

UCSF Long-Term Immunological Impact of Novel Coronavirus Study (LIINC) study was launched early in the pandemic



Reports of post-acute symptoms in hospitalized and non-hospitalized patients emerged early in the pandemic

The Vox logo is displayed in a white, stylized serif font against a solid dark purple rectangular background.

The emerging long-term complications of Covid-19, explained

"It is a true roller coaster of symptoms and severities, with each new day offering many unknowns."

By Lois Parshley | May 8, 2020, 1:10pm EDT

The Science logo features the word "Science" in a white serif font, centered within a solid black rectangular background.

From 'brain fog' to heart damage, COVID-19's lingering problems alarm scientists

By Jennifer Couzin-Frankel | Jul. 31, 2020, 1:30 PM

The New York Times logo is rendered in a black, traditional gothic-style serif font.

Surviving Covid-19 May Not Feel Like Recovery for Some

Debilitating symptoms can last long after a person's body has gotten rid of the coronavirus, a reality Italians are now confronting.



PRESS PLAY WITH MADELEINE BRAND

Think COVID-19 lasts 2 weeks? This patient has been suffering for months


Hosted by Madeleine Brand • Jul. 24, 2020 CORONAVIRUS

Overview


- Long COVID/PASC – SARS-CoV-2 is not the only cause of infection-associated chronic illnesses
- Various “acute” viral infections lead to chronic sequelae – with or without viral persistence over time
- Chronic viral infections (e.g. HIV-1, EBV) may be a model for, or contributor to, infection-associated chronic illnesses
- Potential mechanisms of infection-associated chronic illnesses, including Long COVID
- Other non-viral infection-associated chronic illnesses

LC is Not Alone: RNA Virus Infection & Long-Term Implications

Virus	Sites of RNA persistence	Cell type	Consequences
<i>Picornavirus</i>			
Rhinovirus	Respiratory tract	Epithelial cells?	Asthma
Enterovirus	Heart	Cardiac myocytes	Cardiomyopathy
Hepatitis A	Liver	Hepatocytes	Late hepatitis relapse
Polio	Brain and spinal cord	Motor neurons	Late progression of paralysis and fatigue
<i>Alphavirus</i>			
Chikungunya	Joints	Macrophages	Persistent joint pain
Ross River	Joints	Macrophages	Persistent joint pain
Sindbis	Joints	Macrophages?	Persistent joint pain
<i>Flavivirus</i>			
Zika	Testes	Sertoli cells	Late sexual transmission
Japanese encephalitis	Brain	Neurons	Encephalitis relapse and Parkinson-like disease
West Nile	Kidney?	Unknown	Kidney failure?
Tick-borne encephalitis	Brain	Neurons	Late progressive encephalitis
<i>Coronavirus</i>			
SARS-CoV-2	Respiratory tract and intestine	Epithelial cells and macrophages?	Long COVID/PASC?
<i>Arenavirus</i>			
Lassa	Testes, kidney, and respiratory tract	Sertoli cells?	Epididymitis
<i>Paramyxovirus</i>			
Measles	Lymphoid tissue and brain	Lymphocytes, monocytes, and neurons	Life-long immunity; late progressive CNS disease (SSPE)
Respiratory syncytial	Respiratory tract	Epithelial cells and macrophages?	Chronic pulmonary disease
<i>Filovirus</i>			
Ebola	Testes, eye, and brain	Endothelial cells and macrophages	Late sexual transmission; recurrent/progressive uveitis and encephalitis; postviral syndrome
Marburg	Testes	Sertoli cells	Late sexual transmission



Acute Viral Infections (e.g. Ebola) Can Lead to Persistent Symptoms and Inflammation



- Tiredness
- Headaches
- Muscle and joint pain
- Eye and vision problems
- Weight gain
- Stomach pain or loss of appetite

<https://www.cdc.gov/vhf/ebola/treatment/survivors.html>



Long-lasting severe immune dysfunction in Ebola virus disease survivors

Aurélie Wiedemann¹, Emile Foucat¹, Hakim Hocini¹, Cécile Lefebvre¹, Boris P. Hejblum²,
Mélany Durand², Miriam Krüger², Alpha Kabinet Keita^{3,4}, Ahidjo Ayoub³, Stéphane Mély⁵,
José-Carlos Fernandez¹, Abdoulaye Touré^{3,4,6}, Slim Fourati⁷, Claire Lévy-Marchal⁸, Hervé Raoul⁵,
Eric Delaporte³, Lamine Koivogui⁶, Rodolphe Thiébaud^{2,9}, Christine Lacabartz^{1,11}, Yves Lévy^{1,10,11} &
PostEboGui Study Group*

Median 23 months following discharge:
Increased of blood markers of inflammation, intestinal tissue damage, T cell and B cell activation and exhaustion

Ebola Can Lead to Persistent Infection in Immune Privileged Sites

THE LANCET

Late Ebola virus relapse causing meningoencephalitis: a case report

Michael Jacobs, Alison Rodger, David J Bell, Sanjay Bhagani, Ian Cropley, Ana Filipe, Robert J Gifford, Susan Hopkins, Joseph Hughes, Farrah Jabeen, Ingolfur Johannessen, Drosos Karageorgopoulos, Angie Lackenby, Rebecca Lester, Rebecca S N Liu, Alisdair MacConnachie, Tabitha Mahungu, Daniel Martin, Neal Marshall, Stephen Mephram, Richard Orton, Massimo Palmarini, Monika Patel, Colin Perry, S Erica Peters, Duncan Porter, David Ritchie, Neil D Ritchie, R Andrew Seaton, Vattipally B Sreenu, Kate Templeton, Simon Warren, Gavin S Wilkie, Maria Zambon, Robin Gopal, Emma C Thomson

The NEW ENGLAND JOURNAL of MEDICINE

BRIEF REPORT

Persistence of Ebola Virus in Ocular Fluid during Convalescence

Jay B. Varkey, M.D., Jessica G. Shantha, M.D., Ian Crozier, M.D.,
Colleen S. Kraft, M.D., G. Marshall Lyon, M.D., Aneesh K. Mehta, M.D.,
Gokul Kumar, M.D., Justine R. Smith, M.B., B.S., Ph.D.,
Markus H. Kainulainen, Ph.D., Shannon Whitmer, Ph.D., Ute Ströher, Ph.D.,
Timothy M. Uyeki, M.D., M.P.H., M.P.P., Bruce S. Ribner, M.D., M.P.H.,
and Steven Yeh, M.D.


The NEW ENGLAND JOURNAL of MEDICINE

BRIEF REPORT

Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease

P. Mbala-Kingebeni, C. Pratt, M. Mutafuli-Ruffin, M.G. Pauthner, F. Bile,
A. Nkuba-Ndaye, A. Black, E. Kinganda-Lusamaki, M. Faye, A. Aziza,
M.M. Diagne, D. Mukadi, B. White, J. Hadfield, K. Gangavarapu, N. Bisento,
D. Kazadi, B. Nsunda, M. Akonga, O. Tshiani, J. Misasi, A. Ploquin, V. Epaso,
E. Sana-Paka, Y.T.T. N'kasar, F. Mambu, F. Edidi, M. Matondo, J. Bula Bula,
B. Diallo, M. Keita, M.R.D. Belizaire, I.S. Fall, A. Yam, S. Mulangu, A.W. Rimion,
E. Salfati, A. Torkamani, M.A. Suchard, I. Crozier, L. Hensley, A. Rambaut,
O. Faye, A. Sall, N.J. Sullivan, T. Bedford, K.G. Andersen, M.R. Wiley,
S. Ahuka-Mundeke, and J.-J. Muyembe Tamfum

Large Burden of Acute and Chronic Viral Infections World-Wide



Virgin, Wherry, Ahmed; Cell 2009

HIV-1 RNA and protein expression persists despite suppressive ART

HIV infection

ART

Hepatitis

CMV

EBV

Depletion of and mucos

ICAM-1

VCAM-1

CVDs

IL-6

Premature Thymic Atrophy

IL-6 Early

IL-6 Late

pg/mL

No PASC

PASC

p=0.07

p=0.005

TNF-α

IL-1β

Neurocognitive impairment

OPN

CD57+ CD57+ T cells, T cells

-Terminally differentiated cells (CD28- CD27-) and senescent cells (CD28-CD27-CD57+) both CD4+ and CD8+

-Double Negative B cells (CD27-IgD-)

-Resting Memory B cells (CD27-IgD-)

The Journal of Infectious Diseases

MAJOR ARTICLE

IDSa

hivma

Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection


Michael J. Peluso,¹ Scott Lu,² Alex F. Tang,¹ Matthew S. Durstenfeld,³ Hsi-en Ho,⁴ Sarah A. Goldberg,² Carrie A. Forman,¹ Sadie E. Munter,⁵ Rebecca Hoh,¹ Viva Tai,¹ Ahmed Chenna,⁶ Brandon C. Yee,⁶ John W. Winslow,⁶ Christos J. Petropoulos,⁶ Bryan Greenhouse,¹ Peter W. Hunt,⁵ Priscilla Y. Hsue,³ Jeffrey N. Martin,² J. Daniel Kelly,² David V. Glidden,² Steven G. Deeks,^{1,2} and Timothy J. Henrich^{5,6}

HIV-1 and SARS-CoV-2: Insult on Injury?




Health Status, Persistent Symptoms, and Effort Intolerance One Year After Acute COVID-19 Infection

- **PWH 1.75x as likely to have Long COVID** compared to HIV-negative
- Only 10 PWH in cohort of 530 participants





POST-ACUTE SEQUELAE AND ADAPTIVE IMMUNE RESPONSES IN PEOPLE LIVING WITH HIV RECOVERING FROM SARS-COV-2 INFECTION

- Case-control study of ~40 PWH and matched controls
- **PWH 4x as likely to have Long COVID** compared to HIV-negative



EBV Infection is Inflammatory and Can Lead to Persistent Symptoms



- Sx persist for many weeks (up to 6 months in some individuals)
- Fatigue can be profound
- Risk of HLH/MAS
- EBV has latent and lytic stages & express immune evasion proteins
- Autoreactivity

EBV and Post-Viral Sequelae – The MS Connection?

Science Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis

- Prospective study of 10 million military recruits, 955 diagnosed with MS during study
- Risk of MS increased 32-fold after EBV infection but not after infection with CMV
- NF-L levels went up following EBV infection (neuronal injury)

Bjornevik et al., 2022

Viewpoint Open Access | [10.1172/JCI164141](https://doi.org/10.1172/JCI164141)


Falling down the biological rabbit hole: Epstein-Barr virus, biography, and multiple sclerosis

Ralph I. Horwitz,¹ Allison Hayes-Conroy,² Burton H. Singer,³ Mark R. Cullen,⁴ Kimberly Badal,⁵ and Ida Sim⁶

Published September 1, 2022 - [More info](#)

EBV and Potential Mechanisms of MS

- In MS, B cells gain access to CNS through the blood-brain barrier (BBB)
- Synthesis of immunoglobulins by clonal expansions of plasmablasts within the brain causes oligoclonal immunoglobulin bands
- Cross Reactivity between EBNA1 and glial cell adhesion molecule (GlialCAM) (Lanz et al. 2022)



Human Herpesvirus Reactivation in COVID-19




Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation

67% of people with Long COVID (vs 10% of those with full recovery) had evidence of EBV reactivation (early antigen diffuse IgG titers)




Multiple early factors anticipate post-acute COVID-19 sequelae

Found EBV viremia in early recovery predicted certain persistent symptoms 2-3 months later



Does EBV Reactivation During Acute COVID-19 Lead to Long-Term Sequelae?

EBV EA-D IgG and EBNA IgG Associated with Fatigue and Neurocognitive LC



Brief Communication | [Open Access](#) | 

Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19


Alexandra C. Apple, Alexis Oddi, Michael J. Peluso, Breton M. Asken, Timothy J. Henrich, J. Daniel Kelly, Samuel J. Pleasure, Steven G. Deeks, Isabel Elaine Allen, Jeffrey N. Martin, Lishomwa C. Ndhlovu, Bruce L. Miller, Melanie L. Stephens, Joanna Hellmuth  ... [See fewer authors](#) ^

- Values for CSF white blood cells, glucose, calculated CSF/serum albumin ratio, IgG index, CSF IgG level, and serum IgG level did not differ between participant groups
- Abnormal **oligoclonal banding (OCB)** patterns were identified in **69% (9/13)** of participants with cognitive PASC compared to **0% of cognitive controls** ($p = 0.03$)

Potential Mechanisms of PASC / Long COVID


Acute Infection

Widespread Virus in Tissues




Post-Acute Illness

No RNA/Protein or Viral Persistence



RNA/Protein Tissue Persistence +/- Shedding



Duration of Immune Perturbation and Inflammation in LC

- ^{18}F -AraG PET-CT Imaging in Long COVID – specific marker of activated T cells following antigen exposure (Levi et al. 2022)
- 24 participants, each with prior COVID-19 infection
- 27 to 910 days (2.5 years) out from infection (median 195 days)
- Up to 15 LC symptoms reported (median 6 symptoms)
- 6 reported no LC symptoms

Pre-COVID Control




63 Days After Infection



663 Days After Infection




Increased T Cell Activation In Many Tissues Years Post-COVID-19 Compared to Pre-COVID Controls



Pt 13: 246 Days
Post-COVID

Control 7



Pt 16: 625 Days
Post-COVID

Control 7


Increased tracer uptake in nasopharyngeal tissues, bone marrow, hilar lymph nodes, lung parenchyma, colon/rectal wall, **brain stem**, pulmonary vasculature and **spinal cord** in post-COVID pts compared with pre-COVID controls

SARS-CoV-2 protein persists in gut tissue up to 6 months post-infection

nature

Evolution of antibody immunity to SARS-CoV-2


Christian Gaebler, Zijun Wang, Julio C. C. Lorenzi, Frauke Muecksch, Shlomo Finklin, Minami Tokuyama, Alice Cho, Mila Jankovic, Dennis Schaefer-Babajew, Thiago Y. Oliveira, Melissa Cipolla, Charlotte Viant, Christopher O. Barnes, Yaron Bram, Gaëlle Breton, Thomas Hägglöf, Pilar Mendoza, Arlene Hurley, Martina Turroja, Kristie Gordon, Katrina G. Millard, Victor Ramos, Fabian Schmidt, Yiska Weisblum, Divya Jha, Michael Tankelevich, Gustavo Martinez-Delgado, Jim Yee, Roshni Patel, Juan Dizon, Cecille Unson-O'Brien, Irina Shimeliovich, Davide F. Robbiani, Zhen Zhao, Anna Gazumyan, Robert E. Schwartz, Theodora Hatzioannou, Pamela J. Bjorkman, Saurabh Mehandru, Paul D. Bieniasz, Marina Caskey & Michel C. Nussenzweig - Show fewer authors




Memory B cells display clonal turnover after 6 months, and express a continually evolving antibody response

Viral protein detectable in intestinal biopsies obtained from asymptomatic individuals at month 4 in 7 out of 14 people

SARS-CoV-2 detected throughout the body (including brain) months after infection




Persistent SARS-CoV-2 in Colorectal Tissue - LIINC



158 Days Post COVID-19

Spike RNA in Lamina Propria – some in macrophages



676 Days Post COVID-19

Spike RNA in Lamina Propria – some in macrophages


Unexplained post-acute infection syndromes

Jan Choutka¹, Viraj Jansari², Mady Hornig³ and Akiko Iwasaki^{2,4,5,6}

Table 1 | Overview of unexplained PAISs associated with documented infections

Pathogen	Name of PAIS
Viral pathogens	
SARS-CoV-2	Post-acute sequelae of SARS-CoV-2 infection (PASC) Post-acute COVID-19 syndrome (PACS) Long COVID
Ebola	Post-Ebola syndrome (PES) Post-Ebola virus disease syndrome (PEVDS)
Dengue	Post-dengue fatigue syndrome (PDFS)
Polio	Post-polio syndrome (PPS)
SARS	Post-SARS syndrome (PSS)
Chikungunya	Post-chikungunya chronic inflammatory rheumatism (pCHIK-CIR) Post-chikungunya disease
EBV	No name
West Nile virus	No name
Ross River virus ^a	No name
Coxsackie B ^a	No name
H1N1/09 influenza ^{a,b}	No name
VZV ^{a,b}	
Non-viral pat	
Post-Campylobacter IBS	
<i>Coxiella burnetii</i>	Q fever fatigue syndrome (QFS)
<i>Borrelia</i> ^c	Post-treatment Lyme disease syndrome (PTLDS)
<i>Giardia lamblia</i> ^{a,d}	No name

^aLimited or very limited evidence base. ^bAssociation with increased use of ME/CFS diagnosis in health registry. ^cContradicting or unclear evidence base. ^dSupporting evidence derives from a single outbreak in Norway.



Concluding Thoughts

- **Clear overlap between post-infectious syndromes and chronic viral infections**
(or at least persistence of microbial genetic material and proteins)
- **Just now appreciating the potential for “acute” infections to exhibit some degree of persistence leading to clinical morbidity**
- **Inflammation and dysregulated immunity persists for years following acute infection**
- **Reactivation of existing chronic viral infections in the setting of acute microbial illness may also play an etiologic role**
- **Tissue-based illnesses- need to do “deep dives” and not just study blood**

Concluding Thoughts

- **Etiology of Long COVID likely heterogenous but persistence of SARS-CoV-2 may lay behind many mechanisms**
 - clotting/microangiopathy
 - tissue damage / inflammation
 - dysregulated or autoreactive immune responses
- **The "Post-COVID" era may have new immune/inflammatory set point that needs to be accounted for in prospective research/clinical diagnostics**
 - prior COVID-19 may influence outcomes in studies of other illnesses
 - need for contemporary control groups when studying inflammation/immunity

There may be longer-term impact on human health
(brain, cardiovascular, etc.)

POLYBIOLIINC is a massive team effort



LIINC Leadership Team

- Michael Peluso
- Tim Henrich
- Steve Deeks
- Bryan Greenhouse
- Isabel Rodriguez-Barraquer
- Jeff Martin
- Rachel Rutishauser
- Dan Kelly
- Priscilla Hsue
- Matt Durstenfeld

UCSF Division of HIV/ID/GM

Diane Havlir, Monica Gandhi, Matt Spinelli, Annie Luetkemeyer, Vivek Jain, Sulggi Lee, Laurence Huang

SCOPE/LIINC Clinical Research Team

Becky Hoh, Viva Tai, Meghann Williams, Monika Deswal, Mireya Arreguin, Dylan Ryder, Lynn Ngo, Sadie Munter, Melissa Buitrago, James Lombardo

LIINC-Coronavirus Neurocognitive Study Team

Joanna Hellmuth, Felicia Chow, Meredith Greene, Alexis Oddi

LIINC-Cardiovascular Impact Study Team

Priscilla Hsue, Matt Durstenfeld, Shreya Swaminathan, Victor Arechiga, Danny Li

LIINC-Social Science Team

John Saucedo, Edda Santiago Rodriguez

FIND/LIINC Clinical Epidemiology Team

Khamal Anglin, Scott Lu, Sarah Goldberg, Sujata Mathur, Jessica Chen, Gustavo Castellanos

Henrich Lab

Amelia Deitchman, Micheal Peluso, Tyler-Marie Deveau, Amanda Buck, Brain LeFranchi, Dylan Ryder, Isaac Thomas, Kofi Asare, Marine Lyden

Monogram Biosciences

Chris Petropoulos, John Winslow, Ahmed Chenna, Brandon Yee

Greenhouse Lab

Andino Lab

Core Immunology Laboratory
AIDS Specimen Bank

Medical Students

Michelle Davidson, Hannah Sans, Jonathan Massachi, Kevin Donohue, Enrique Martinez, Allen Barnett, Alex Tang, Carrie Forman, Victoria Murray

Former LIINC Team Members

Marian Kerbleski, Heather Hartig, Fatima Ticas, Tamara Abualhsan, Andrea Alvarez, Yanel Hernandez, Emily Fehrman, Leo Torres, Jill Hakim, Keirstinne Turcios, Owen Jansen



Grants

PolyBio Research Foundation
NIAID AI141003 (Henrich); Merck (Henrich)
NIAID AI158013 (Gandhi/Spinelli)
K23AI157875 (Peluso)
UCSF Resource Allocation Program & CFAR

Greater Decline SARS-CoV-2-Specific CD8+ T Cell Responses in Participants who Develop PASC 4 Months after Acute Infection

Cell Reports

Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms



Persistent Inflammation 8 Months Following COVID-19

